Zhang Yan-Li, Ding Chao, Sun Lei
Medical Department, Maternity and Child Care centers, Zaozhuang 277100, Shandong Province, China.
Zaozhuang Hospital of Zaozhuang Mining Group, Zaozhuang 277100, Shandong Province, China.
Open Med (Wars). 2019 Feb 26;14:251-258. doi: 10.1515/med-2019-0020. eCollection 2019.
Liver cancer is one of the most malignant tumors with poor prognosis. Finding molecular markers that can predict prognosis is very important for the treatment of liver cancer. The present research is trying to find a new biomarker for human liver cancer. The analysis of abnormal expression genes and prognosis value on liver cancer by Gene Expression Profiling Interactive Analysis (GEPIA) database, the Pathology Atlas of the Human Protein Atlas (HPA), and Kaplan Meier-plotter (KM plotter), proved that B3GAT3 might be one of the important candidates. Furthermore, we investigated the specific role of B3GAT3 on liver cancer through the transfection of B3GAT3 siRNA in HepG2 cells. The proliferation was detected using CCK8, and migration and invasion were determined using Transwell assay. Our results proved that knockdown of B3GAT3 inhibited the proliferation, migration, and invasion. Moreover, B3GAT3 knockdown inhibited the expression of EMT related proteins, N-cad, Snail, and Twist, while promoting the expression of E-cad, suggesting that B3GAT3 knockdown reversed the EMT process of liver cancer cells. In conclusion, overexpressed B3GAT3 promotes the process of tumor EMT, which is an independent prognostic marker to predict the prognosis of liver cancer and might be a potential new target for liver cancer therapy.
肝癌是预后较差的最恶性肿瘤之一。寻找能够预测预后的分子标志物对于肝癌治疗非常重要。目前的研究试图找到一种用于人类肝癌的新生物标志物。通过基因表达谱交互分析(GEPIA)数据库、人类蛋白质图谱病理图谱(HPA)以及Kaplan Meier绘图仪(KM绘图仪)对肝癌异常表达基因和预后价值进行分析,证明B3GAT3可能是重要候选物之一。此外,我们通过在HepG2细胞中转染B3GAT3 siRNA来研究B3GAT3在肝癌中的具体作用。使用CCK8检测增殖情况,使用Transwell实验测定迁移和侵袭能力。我们的结果证明,敲低B3GAT3可抑制增殖、迁移和侵袭。此外,敲低B3GAT3可抑制EMT相关蛋白N-cad、Snail和Twist的表达,同时促进E-cad的表达,这表明敲低B3GAT3可逆转肝癌细胞的EMT过程。总之,B3GAT3过表达促进肿瘤EMT过程,它是预测肝癌预后的独立预后标志物,可能是肝癌治疗的潜在新靶点。